RS52115B - NEW FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES BINDING ON HUMAN LEUKOCYTIC ANTIGEN (HLA) CLASS I OR II MOLECULES FOR VACCINES - Google Patents
NEW FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES BINDING ON HUMAN LEUKOCYTIC ANTIGEN (HLA) CLASS I OR II MOLECULES FOR VACCINESInfo
- Publication number
- RS52115B RS52115B RS20110588A RSP20110588A RS52115B RS 52115 B RS52115 B RS 52115B RS 20110588 A RS20110588 A RS 20110588A RS P20110588 A RSP20110588 A RS P20110588A RS 52115 B RS52115 B RS 52115B
- Authority
- RS
- Serbia
- Prior art keywords
- hla
- tumour
- vaccines
- molecules
- class
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 3
- 229930195725 Mannitol Natural products 0.000 abstract 3
- 235000010355 mannitol Nutrition 0.000 abstract 3
- 239000000594 mannitol Substances 0.000 abstract 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 2
- 229920001993 poloxamer 188 Polymers 0.000 abstract 2
- 229940044519 poloxamer 188 Drugs 0.000 abstract 2
- 229920000136 polysorbate Polymers 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4766908P | 2008-04-24 | 2008-04-24 | |
| EP08008292A EP2113253B1 (fr) | 2008-04-30 | 2008-04-30 | Nouvelles formules de peptides associées aux tumeurs à liaison aux molécules II ou I de classe d'antigène (HLA) de leucocyte humain pour vaccins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS52115B true RS52115B (en) | 2012-08-31 |
Family
ID=39643855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20110588A RS52115B (en) | 2008-04-24 | 2009-04-23 | NEW FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES BINDING ON HUMAN LEUKOCYTIC ANTIGEN (HLA) CLASS I OR II MOLECULES FOR VACCINES |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9289478B2 (fr) |
| EP (2) | EP2113253B1 (fr) |
| JP (1) | JP5717268B2 (fr) |
| CN (1) | CN105749285A (fr) |
| AT (2) | ATE462442T1 (fr) |
| AU (1) | AU2009201589C1 (fr) |
| BR (1) | BRPI0900798A8 (fr) |
| CA (1) | CA2665510C (fr) |
| CY (1) | CY1110178T1 (fr) |
| DE (1) | DE602008000891D1 (fr) |
| DK (2) | DK2113253T3 (fr) |
| EA (1) | EA017492B1 (fr) |
| ES (2) | ES2342506T3 (fr) |
| HR (2) | HRP20100354T1 (fr) |
| MX (1) | MX2009004468A (fr) |
| NZ (1) | NZ576423A (fr) |
| PL (2) | PL2113253T3 (fr) |
| PT (2) | PT2113253E (fr) |
| RS (1) | RS52115B (fr) |
| SI (2) | SI2113253T1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| EP2565204B1 (fr) | 2007-07-27 | 2015-10-07 | immatics biotechnologies GmbH | Nouveaux épitopes immunogènes pour l'immunothérapie |
| SI2183361T1 (sl) | 2007-07-27 | 2015-09-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti nevronalnim in možganskim tumorjem |
| CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
| ES2532896T5 (es) * | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| RS54233B1 (en) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| SI2172211T1 (sl) * | 2008-10-01 | 2015-03-31 | Immatics Biotechnologies Gmbh | Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka |
| AU2016204710B2 (en) * | 2008-10-01 | 2018-02-22 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| NZ609916A (en) * | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013041542A1 (fr) * | 2011-09-19 | 2013-03-28 | Alf Lamprecht | Formulations pharmaceutiques comprenant des sphérolyophilisats de molécules biologiques |
| KR20140138900A (ko) | 2012-03-09 | 2014-12-04 | 온코세라피 사이언스 가부시키가이샤 | 펩티드를 포함한 의약 조성물 |
| WO2013192493A1 (fr) * | 2012-06-21 | 2013-12-27 | Phosphorex, Inc. | Nanoparticules d'indirubine, leurs dérivés et leurs procédés de fabrication et d'utilisation |
| TWI777198B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| US10568948B2 (en) | 2015-05-13 | 2020-02-25 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| IL307401A (en) * | 2015-06-19 | 2023-12-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy and methods for creating scaffolds for use against pancreatic cancer and other types of cancer. |
| CA2936070C (fr) * | 2015-07-14 | 2023-07-04 | Professional Compounding Centers Of America (Pcca) | Injections intralesions a base de poloxamere destinees a administrer des agents chimiotherapeutiques |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| WO2018138257A1 (fr) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| RS64217B1 (sr) * | 2017-01-27 | 2023-06-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
| JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
| FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| CN115697374A (zh) * | 2020-05-12 | 2023-02-03 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| WO2023148333A1 (fr) | 2022-02-03 | 2023-08-10 | CeCaVa GmbH & Co. KG | Co-vaccination avec des antigènes cd4 et cd8 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045796A (en) * | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| AU716785B2 (en) * | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE19917195B4 (de) | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| CA2386088A1 (fr) * | 1999-10-19 | 2001-04-26 | Ludwig Institute For Cancer Research | Peptides antigeniques mage-a12 et utilisation |
| US6897288B1 (en) * | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP1517698B2 (fr) * | 2002-06-21 | 2017-12-06 | Novo Nordisk Health Care AG | COMPOSITIONS SOLIDES STABILISEES DE POLYPEPTIDES DE FACTEUR VIIa |
| EP1569514A4 (fr) * | 2002-08-16 | 2007-10-31 | Antigene specifique de tumeurs, peptides associes et utilisation de ceux-ci en tant que vaccins antitomoraux | |
| JP2007525448A (ja) * | 2003-04-11 | 2007-09-06 | アンティジェニクス インコーポレーテッド | 改良された熱ショックタンパク質に基づくワクチンおよび免疫治療 |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| EP1674082A1 (fr) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament |
| ATE512160T1 (de) | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
| EP1806359B1 (fr) | 2005-09-05 | 2010-03-17 | Immatics Biotechnologies GmbH | Peptides associeés a des tumeurs et se liantes a des différentes antigènes d'histocompatibilité (HLA) de classe II |
| ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| WO2007028753A2 (fr) | 2005-09-09 | 2007-03-15 | Basf Aktiengesellschaft | Melanges fongicides a base de triazoles |
| US20080242606A1 (en) * | 2006-06-06 | 2008-10-02 | Zhong Jiang | Use of IMP3 as a Prognostic Marker for Cancer |
| ES2532896T5 (es) * | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| SI2172211T1 (sl) * | 2008-10-01 | 2015-03-31 | Immatics Biotechnologies Gmbh | Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka |
-
2008
- 2008-04-30 PL PL08008292T patent/PL2113253T3/pl unknown
- 2008-04-30 SI SI200830038T patent/SI2113253T1/sl unknown
- 2008-04-30 ES ES08008292T patent/ES2342506T3/es active Active
- 2008-04-30 PT PT08008292T patent/PT2113253E/pt unknown
- 2008-04-30 AT AT08008292T patent/ATE462442T1/de active
- 2008-04-30 DK DK08008292.8T patent/DK2113253T3/da active
- 2008-04-30 DE DE602008000891T patent/DE602008000891D1/de active Active
- 2008-04-30 EP EP08008292A patent/EP2113253B1/fr active Active
-
2009
- 2009-04-23 PT PT09005725T patent/PT2111867E/pt unknown
- 2009-04-23 DK DK09005725.8T patent/DK2111867T3/da active
- 2009-04-23 EA EA200900487A patent/EA017492B1/ru not_active IP Right Cessation
- 2009-04-23 NZ NZ576423A patent/NZ576423A/en not_active IP Right Cessation
- 2009-04-23 RS RS20110588A patent/RS52115B/en unknown
- 2009-04-23 ES ES09005725T patent/ES2374138T3/es active Active
- 2009-04-23 PL PL09005725T patent/PL2111867T3/pl unknown
- 2009-04-23 AT AT09005725T patent/ATE526979T1/de active
- 2009-04-23 CN CN201610085112.0A patent/CN105749285A/zh active Pending
- 2009-04-23 US US12/428,893 patent/US9289478B2/en active Active
- 2009-04-23 JP JP2009104886A patent/JP5717268B2/ja active Active
- 2009-04-23 SI SI200930119T patent/SI2111867T1/sl unknown
- 2009-04-23 EP EP09005725A patent/EP2111867B1/fr active Active
- 2009-04-23 AU AU2009201589A patent/AU2009201589C1/en not_active Ceased
- 2009-04-24 CA CA2665510A patent/CA2665510C/fr not_active Expired - Fee Related
- 2009-04-24 BR BRPI0900798A patent/BRPI0900798A8/pt not_active Application Discontinuation
- 2009-04-24 MX MX2009004468A patent/MX2009004468A/es active IP Right Grant
-
2010
- 2010-06-09 CY CY20101100508T patent/CY1110178T1/el unknown
- 2010-06-28 HR HR20100354T patent/HRP20100354T1/hr unknown
-
2011
- 2011-12-21 HR HR20110965T patent/HRP20110965T1/hr unknown
-
2012
- 2012-01-09 US US13/346,197 patent/US9283267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS52115B (en) | NEW FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES BINDING ON HUMAN LEUKOCYTIC ANTIGEN (HLA) CLASS I OR II MOLECULES FOR VACCINES | |
| HRP20191852T1 (hr) | Polipeptidi | |
| RS53782B1 (en) | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS | |
| HRP20170433T1 (hr) | Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci | |
| JP6063094B2 (ja) | 経皮送達を促進するためのペプチド | |
| Hussein et al. | Multiantigenic peptide–polymer conjugates as therapeutic vaccines against cervical cancer | |
| CN101687022A8 (zh) | Prame衍生的肽以及包括该肽的免疫原组合物 | |
| WO2007054283A3 (fr) | Pqs et leurs conjugues utiles en tant qu'adjuvants et leurs utilisations dans des compositions pharmaceutiques | |
| ES2735274T3 (es) | Nuevo método inmunoestimulador | |
| WO2006076620A3 (fr) | Compositions pharmaceutiques de bendamustine | |
| PE20071063A1 (es) | Formulaciones de proteinas estables | |
| US20230390389A1 (en) | Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines | |
| JP2015533376A5 (fr) | ||
| RU2010107207A (ru) | Новые синтетические агонисты tlr9 | |
| NO20023829D0 (no) | Proteosom influensavaksine | |
| ES2494316T3 (es) | Ingrediente activo novedoso en cicatrización y uso del mismo | |
| JP2003526681A (ja) | 輸送分子結合特性を含む治療用及び診断用リガンドシステム並びに同含有薬剤 | |
| WO2007061829A3 (fr) | Composition pharmaceutique | |
| JP2010530362A5 (fr) | ||
| JP2014508734A5 (fr) | ||
| RU2008114841A (ru) | Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса | |
| ECSP13012398A (es) | Un nuevo estable polietileno glicol conjugado de interferon alfa, representado por un iso?mero | |
| BRPI0720230B8 (pt) | formulação nutricional oralmente administrável, uso da formulação, e, composição | |
| ATE287957T1 (de) | Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus | |
| DE69530380D1 (de) | Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik |